Short Interest in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Increases By 169.5%

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 517,820 shares, a growth of 169.5% from the July 15th total of 192,173 shares. Based on an average daily trading volume, of 7,426,518 shares, the short-interest ratio is presently 0.1 days. Approximately 3.6% of the shares of the company are short sold.

Kairos Pharma Stock Down 5.3%

KAPA traded down $0.02 during trading hours on Friday, hitting $0.34. The stock had a trading volume of 184,341 shares, compared to its average volume of 2,438,974. Kairos Pharma has a 1 year low of $0.27 and a 1 year high of $2.11. The company’s fifty day simple moving average is $0.37 and its 200 day simple moving average is $0.51. The stock has a market cap of $7.30 million, a PE ratio of -1.22 and a beta of 1.56.

Get Kairos Pharma alerts:

Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter. As a group, equities analysts expect that Kairos Pharma will post -0.37 EPS for the current year.

Institutional Investors Weigh In On Kairos Pharma

A hedge fund recently raised its stake in Kairos Pharma stock. XTX Topco Ltd grew its stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Free Report) by 290.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 48,494 shares of the company’s stock after acquiring an additional 36,086 shares during the period. XTX Topco Ltd owned 0.23% of Kairos Pharma worth $34,000 at the end of the most recent reporting period.

Kairos Pharma Company Profile

(Get Free Report)

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.

See Also

• Five stocks we like better than Kairos Pharma
• Is Best Buy the AI Winner Hiding in the Electronics Aisle?
• Applied Materials Beat Everything but Wall Street’s Expectations for Margins
• Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
• Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing

Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.